These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26511599)

  • 21. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.
    Fici F; Ari Bakir E; Ilkay Yüce E; Kanuncu S; Makel W; Tarim BA; Robles NR
    High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):43-49. PubMed ID: 31916208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.
    Persson F; Rossing P; Reinhard H; Juhl T; Stehouwer CD; Schalkwijk C; Danser AH; Boomsma F; Frandsen E; Parving HH
    Diabetologia; 2010 Aug; 53(8):1576-80. PubMed ID: 20480132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
    JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study.
    Renke M; Lizakowski S; Tylicki L; Rutkowski P; Knap N; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Januszczyk J; Wójcik-Stasiak M; Małgorzewicz S; Woźniak M; Rutkowski B
    Adv Med Sci; 2014 Sep; 59(2):256-60. PubMed ID: 25105662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients.
    García-Donaire JA; Segura J; Cerezo C; Ruilope LM
    Blood Press; 2011 Dec; 20(6):322-34. PubMed ID: 21936729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
    Sever PS; Gradman AH; Azizi M
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
    McMurray JJ; Krum H; Abraham WT; Dickstein K; Køber LV; Desai AS; Solomon SD; Greenlaw N; Ali MA; Chiang Y; Shao Q; Tarnesby G; Massie BM;
    N Engl J Med; 2016 Apr; 374(16):1521-32. PubMed ID: 27043774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum uric acid level is associated with metabolic syndrome and microalbuminuria in Korean patients with type 2 diabetes mellitus.
    Kim ES; Kwon HS; Ahn CW; Lim DJ; Shin JA; Lee SH; Cho JH; Yoon KH; Kang MI; Cha BY; Son HY
    J Diabetes Complications; 2011; 25(5):309-13. PubMed ID: 21130003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct renin inhibitor induced renal failure.
    Vallakati A; Chandra PA; Hollander G; Shani J
    Am J Ther; 2014; 21(2):e53-5. PubMed ID: 23665882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.
    Messerli FH; Bangalore S
    Am J Med; 2013 Mar; 126(3):e1-3. PubMed ID: 23332648
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.